Clinical Practice Guidelines
DEAR SIR, I am writing to you regarding the 'Summary of guideline for the treatment of bipolar disorder', published in your March 2003 issue, 1 which is in general an excellent paper. However, it does not take into account the realities of everyday private practice.
For example, the drug Lamotrigine is recommended on a number of occasions throughout the article: on p. 49 as a mood stabilizer in bipolar depression, on p. 51 as a second choice for rapid cycling and first choice for non-rapid cycling. Even though this medication has significant published literature to support these recommendations, it is not currently available in Australia for the indications outlined and under the Pharmaceutical Benefits Scheme (PBS) it is approved for use only in 'epileptic seizures not controlled by other antiepileptic drugs'; its only use both on and off the PBS is in 'partial and generalized seizures in adults and children'. I raise this point because, after reading the summary of treatment guidelines and having read the very similar American equivalent, I contacted the drug company that markets Lamotrigine (known as Lamictal in Australia), Glaxo, Smith Kline and I was told that this drug is currently not indicated for use in mood disorders in Australia and, furthermore, that the company is not currently marketing the drug to psychiatrists in Australia. I was told in no uncertain terms that until approval was granted by the Therapeutic Goods Administration for those indications, I would be using the drug against the company's wishes and at my own risk.
Perhaps one of the problems with expert committees is that they do not have on them anyone in everyday private practice. I noticed that the Royal Australian and New Zealand College of Psychiatrists Clinical Practice Guideline Team for Bipolar Disorder included a professor of psychiatry, a senior lecturer at the school of psychiatry, a research officer, and a research psychologist. In fact, more than half of the College members are in private practice where recommendations like these are unable to be used; unfortunately, we are much more open to the dangers of litigation than persons protected by large institutions.
I hope this letter can be taken as constructive criticism and perhaps, in future, the non-approved status of a drug can be highlighted, even with a cautionary note about off-label usage.
